Home・Список акций・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Открыт

СекторЗдравоохранение

82.32 -0.82

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

81.96

Макс.

83.56

Ключевые показатели
By Trading Economics
Доход	11M -156M
Продажи	28M 222M
Прибыль на акцию	-0.78
Рентабельность продаж	-70.082
Сотрудники	999
EBITDA	-24M -137M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+30.89% upside

Дивиденды
By Acuity
Следующий отчет о доходах	28 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-981M 16B
Предыдущая цена открытия	83.14
Предыдущая цена закрытия	82.32

Новостные настроения

By Acuity

50%

171 / 340 Рейтинг в Healthcare

Bridgebio Pharma Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 авг. 2026 г., 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19 авг. 2026 г., 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18 авг. 2026 г., 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14 авг. 2026 г., 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13 авг. 2026 г., 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12 авг. 2026 г., 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11 авг. 2026 г., 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10 авг. 2026 г., 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7 авг. 2026 г., 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6 авг. 2026 г., 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5 авг. 2026 г., 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4 авг. 2026 г., 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3 авг. 2026 г., 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31 июл. 2026 г., 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30 июл. 2026 г., 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29 июл. 2026 г., 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28 июл. 2026 г., 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27 июл. 2026 г., 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Сравнение c конкурентами

Изменение цены

Bridgebio Pharma Inc Прогноз

Целевая цена

By TipRanks

30.89% рост

Прогноз на 12 месяцев

Средняя 108.56 USD 30.89%

Максимум 157 USD

Минимум 94 USD

Основано на мнении 17 аналитиков Wall Street, спрогнозировавших целевые цены для Bridgebio Pharma Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

17 ratings

Покупка

Удержание

Продажа

Основано на мнении 17 аналитиков, присваивавших рейтинги акциям Bridgebio Pharma Inc – Данные за последние 3 месяца.

Настроения

By Acuity

171 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.